O
HZNP

OppenheimerFunds’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

OppenheimerFunds’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-588,993
Closed -$9.32M – 985
2014
Q2 		$9.32M Buy
+588,993
New +$8.41M 0.01% 765

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds's HZNP Position: Q3 2014 in Review

OppenheimerFunds sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2014, closing a stake of 588,993 shares — an estimated $9.32M sold.

OppenheimerFunds first reported a position in HZNP in Q2 2014 and held it in 1 quarter. The position peaked at $9.32M in Q2 2014. 120 funds tracked by Wall St. Rank hold HZNP as of Q3 2014.

  • OppenheimerFunds reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2014 after selling out during the quarter.
  • OppenheimerFunds sold 588,993 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2014, an estimated $9.32M.
  • OppenheimerFunds first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 1 quarter.
  • OppenheimerFunds's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $9.32M in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2014.

Based on OppenheimerFunds's 13F filing for Q3 2014, filed 13 Nov 2014.